Antimicrobial development in the era of emerging resistance

Sorlozano Puerto, Antonio; Carrasco, Cristina; Cabeza, José; Villegas Martínez, Enrique; Gutiérrez Fernández, José

doi:10.2174/138955709788681564

Antimicrobial_Development_in_the_Era_of.pdf (348.1Ko)

Identificadores

URI: https://hdl.handle.net/10481/90659

DOI: 10.2174/138955709788681564

Exportar

Editorial

Bentham Science Publishers

Materia

Faropenem

Dalbavancin

Telavancin

Oritavancin

Ceftobiprole

Iclaprim

Date

2009-07

Referencia bibliográfica

Sorlozano A, Carrasco C, Cabeza J, Villegas E, Gutierrez J. Antimicrobial development in the era of emerging resistance. Mini Rev Med Chem. 2009 Jul;9(8):938-55. DOI:10.2174/138955709788681564

Résumé

Antibiotics currently under study by the Food and Drugs Administration include: faropenem (for treatment of sinusitis, bronchitis, and community-acquired pneumonia), dalbavancin (for catheter infections), telavancin (for treatment of nosocomial pneumonia), oritavancin (for bacteremia), ceftobiprole and iclaprim (for pneumonias). Moreover, all of them would be useful for skin and soft tissue infections.

Colecciones

DM - Artículos

Excepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 Internacional